Ambrx Biopharma Market Cap 2020-2021 | AMAM

Ambrx Biopharma market cap history and chart from 2020 to 2021. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Ambrx Biopharma market cap as of August 10, 2022 is $0.09B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.089B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00